Syngene International Limited

#CaseStudy! Learn how Syngene developed a robust and scalable Green GMP manufacturing process for an oncology drug compound in just eight weeks, which reduced costs by 30%. Read the full case study 👉 https://lnkd.in/ga6HX53g #GreenChemistry #Biopharma #GoGreenAtSyngene

We are excited to attend the Biotech Showcase 2025 from January 13-15, 2025 in San Francisco, CA. Meet our experts to discuss how Syngene can help you accelerate your drug discovery programs.   To book a meeting, visit https://lnkd.in/gCqrUPJU   Our Discovery Services span the entire spectrum of early-stage research from target identification to delivery of drug candidates for further development. In Small Molecules, our services cover Chemistry, Biology, Safety Assessment & Toxicology, and Research Informatics. In Biologics, our services cover recombinant DNA engineering, cell line development, hybridoma technology, Next-Generation Sequencing, and protein sciences (purification & crystallography).   What sets us apart in Discovery Services, is our ability to seamlessly connect discovery and development, our target-focused modality, and our therapeutic area–agnostic approach. In addition, is our collaborative partnership model, supported by robust logistics, streamlined project management, and cutting-edge IT infrastructure. To know more, contact us now. #DrugDiscovery #Syngene #Biotechshowcase2024 

Mammalian Gene to GMP – Know Your Timeline in Advance! At Syngene, we’re committed to reducing uncertainties in biologics development, helping you plan smarter and execute flawlessly. Our unique Biologics Timeline Tool allows you to instantly estimate your molecule’s development journey. Simply fill in the details, hit ‘Submit,’ and know your timeline from Gene to GMP in seconds. With Syngene, you can start within 4 weeks, experience a streamlined process from CLD to the clinic in 10 months, and stay connected through real-time data sharing. Our flexible manufacturing capacity, ranging from 50L to 2KL SUB, ensures scalability to meet your needs. We offer an end-to-end in-house service, providing everything from cell line development to clinical manufacturing. Try our tool today and take the first step toward a seamless biologics development journey! Get started 👉 https://lnkd.in/gMbVp89b #GenetoGMP #SyngeneBiologics #Antibody #mAb

In ET Pharma's year-end roundup on the Indian pharmaceutical sector, Alok Mehrotra, Syngene's Chief Quality Officer, shares insights on the evolving landscape of Indian Contract Research, Development, and Manufacturing Organizations (CRDMOs). He discusses how the industry is driving progress through its commitment to a "first-time-right" approach, technological advancements, sustainability, and workforce development. Additionally, he highlights various factors that can help Indian CRDMOs effectively position themselves within the global pharmaceutical landscape. Read the full article – https://lnkd.in/gWzqu7ez #Syngene #CRDMO

Are you looking for a partner to support all phases of clinical development?   Discover Syngene's extensive range of Clinical Laboratory and Bioanalytical services designed to support all phases of clinical development. Our capabilities include: -Bioanalytical Laboratory for Biologics: GLP-certified, specializing in PK, PD, and immunogenicity of biotherapeutics. -Bioanalytical Laboratory for Small Molecules: Method development, validation, bioanalysis for TDM, BA/BE, and PK studies. -Central Laboratory: CAP-accredited, offering clinical study support, assay development, and biomarker services.   Our state-of-the-art integrated solutions and facilities provide high-quality, reliable, and innovative services tailored to meet your clinical development needs from early-phase trials to commercialization.   Get in touch with our experts today 👉 https://lnkd.in/gRbdAmit #ClinicalTrials #ClinicalDevelopment #Syngene

Ensuring the safety, containment, analysis, and production of potent compounds at every stage, from development to commercialization. This facility has been meticulously designed to adeptly handle cytotoxic and cytostatic high-potency compounds, demonstrating a commitment to safety with an occupational exposure limit (OEL) of up to 0.01 µg/m, over an 8-hour period, categorizing it within Band 4/5. Operating under current Good Manufacturing Practices (cGMP), the facility is positioned to meet the stringent requirements of the regulated market. Additionally, it boasts an integrated cGMP facility dedicated to the production of non-potent compounds. To further augment its capacity and capabilities, the facility is equipped with the flexibility to incorporate additional reactors and corresponding downstream equipment. The designed batch capacity stands at an impressive 30 kg, underlining the facility's efficiency and scalability in accommodating the production demands of potent pharmaceutical compounds. For more information, contact us https://lnkd.in/gCqrUPJU #DrugDevelopment #HPAPI #Syngene

Looking for advanced bioanalytical services to support your biopharma research and development? The Centre for Advanced Protein Studies (CAPS), located at the Syngene campus in Bangalore, offers cutting-edge analytical capabilities for startups, SMEs, academic labs, and biopharma companies. Established with funding from BIRAC-DBT as part of the National Biopharma Mission, CAPS is a collaborative effort between the Government of India and Syngene International Ltd., providing specialized support for product development and regulatory compliance. CAPS provides a range of high-quality analytical services, including: • Comprehensive protein characterization and bioassay studies using mass spectrometry • Peptide Mapping, Biosimilar Assessment, and Charge Variant Analysis • Advanced techniques such as Surface Plasmon Resonance, HPLC/UPLC, and Capillary Electrophoresis • Method development, qualification studies, and sample analysis With a GLP-accredited lab and a team of experienced scientists, CAPS offers technical expertise and regulatory guidance, supporting projects from early development through to completion. Our goal: To provide scientific communities with the analytical tools and insights necessary to meet global standards and drive innovation in biopharma research and development. To learn more about our CAPS capabilities, visit 👉 https://lnkd.in/guaaCHxF #BioanalyticalServices #ProteinCharacterization #Biopharma #DrugDevelopment #Syngene #CAPS #BIRAC

Early discovery to cGMP manufacturing! Together with our state-of-the-art facility, a highly qualified team of scientists, and global client experience, we have all it takes to become the partner of choice for companies looking to accelerate their oligonucleotide programs. Synthesize high purity, stable Antisense Oligonucleotides (ASOs) at rapid turnaround time with Syngene’s comprehensive range of services from discovery to cGMP manufacturing (1g to 1 kg) Our expertise encompasses the following areas – ⦿ Chemically synthesized high-quality modified and non-modified custom oligonucleotide (DNA/RNA) ⦿ siRNA (single & double-stranded) ⦿ miRNA (modified and non-modified) ⦿ Antisense Oligonucleotides ⦿ Phosphothioates and Morpholinos ⦿ All types of Oligo Conjugates ⦿ All types of base & custom modifications For more information, contact us at https://lnkd.in/gCqrUPJU #Oligonucleotides #Biotech #cGMPManufacturing #Biopharma #Syngene

High titers and shorter timelines are essential for efficient protein production. Enhancing gene expression consistency during the cell line development stage is a crucial strategy to overcome this challenge. Check out our latest feature on BioPharma Dive, where we explore the key bottlenecks in gene expression and share effective solutions to streamline processes and improve reliability. Read the full article 👉 https://lnkd.in/gxuY9dEf #Biologics #ProteinProduction #GeneExpression #CellLineDevelopment #Syngene #Biopharma #ResearchInnovation #SynWeave

Our high-quality iPSC products & services offer a game-changing approach to disease modelling & therapy development. Generate top-tier iPSCs, ensure high quality & robustness for your research needs with our expertise. From reprogramming to advanced gene editing using CRISPR to novel drug screening, we’ve got you covered. Get in touch to learn more about our iPSC services👉 https://lnkd.in/gZUAJdS9 Our product offerings include - ⦿ iPSC generation from healthy and diseased samples. ⦿ Gene editing in iPSCs (CRISPR) for disease modeling and drug screening. ⦿ Differentiation of iPSCs into multiple cell lineages (cardiomyocytes, neurons, hematopoietic stem cells, T cells). ⦿ iPSC derived cell-based assays and immune assays. #iPSC #CRISPR #DrugDiscovery